Oppenheimer Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

By Ryan Adsit

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMDResearch Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $5.23.

Olson observed:

“TXMD provided an update on the Imvexxy launch and a competitor reported 4Q18 results yielding insights into VVA market dynamics and reimbursement. TXMD’s periodic Imvexxy launch updates provide valuable information in the absence of meaningful audited script data. We’re encouraged by several important metrics, including: 1) Imvexxy scripts grew 19% (month/month) in Jan to continue on a best-in-class trajectory, 2) based on Jan alone, Imvexxy still outpaces the most recent competitive launch from a quarterly perspective, 3) read-across from a recent competitive launch points to 60% achievability for net pricing, and 4) United Health is added to growing list of Imvexxy coverage. We remain optimistic about TXMD shares with 3 launches in 2019 described in our recent report. Maintain Outperform with details inside.”

According to TipRanks.com, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.4% and a 37.1% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on TherapeuticsMD is a Moderate Buy with an average price target of $20.50, a 292.0% upside from current levels. In a report issued on January 31, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

Based on TherapeuticsMD’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $35.61 million. In comparison, last year the company had a GAAP net loss of $21.43 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.